1
|
Giacomazzi J, Correia RL, Palmero EI, Gaspar JF, Almeida M, Portela C, Camey SA, Reis RM, Ashton-Prolla P. Abstract P2-13-01: The Brazilian founder TP53 p.R337H mutation is uncommon in Portuguese women diagnosed with breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Since the first studies reporting the TP53 p.R337H mutation as founder mutation in Southern and Southeastern regions of Brazil, both in the general population and in patients from high risk breast cancer families with adrenocortical, choroid plexus and breast carcinomas, there has been controversy on the origin of this mutation. Preliminary analysis of the small subset of Brazilian mutation carriers that defined the founder haplotype using 29 tag SNPs revealed that the haplotype incided on a Caucasian background. The vast majority of carriers identified today reside in Brazil or, if identified in other countries, are Brazilian immigrants. To our knowledge, the only two exceptions of carriers without a recognizable link with Brazil are two European families (one Portuguese and one German) (Chompret et al., 2000; Herrmann et al. 2012). Haplotype analysis in the Portuguese family revealed the same haplotype identified in Brazilian individuals, but in the German family, a distinct haplotype was found. Knowing that a significant proportion of women with breast cancer in Southern Brazil are p.R337H carriers, we initiated TP53 genotyping in a Portuguese cohort of women with breast cancer recruited from the cities of Lisboa and Braga. Median age at diagnosis of breast cancer among the first 573 patients tested was 60 years and 100 (17.4%) patients had been diagnosed at or under the age of 45 years. Mutation screening was performed using Real-Time PCR (taqman assays), and failed to identify the mutation in the 573 patients tested. These results are in contrast with the mutation frequency observed in a study of 815 breast cancer-affected women from Southern and Southeastern Brazil, which has reached frequencies of 12.1 and 5.1% in pre- and post-menopausal women, respectively (Ashton-Prolla et al. 2012; ASCO Annual Meeting, ref 1522). We conclude that there is a significant difference in mutation frequency observed between the two cohorts (p<0.001). These findings suggest that TP53 p.R337H is not a common molecular alteration in Portuguese breast cancer-affected patients.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-13-01.
Collapse
Affiliation(s)
- J Giacomazzi
- Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal
| | - RL Correia
- Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal
| | - EI Palmero
- Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal
| | - JF Gaspar
- Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal
| | - M Almeida
- Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal
| | - C Portela
- Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal
| | - SA Camey
- Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal
| | - RM Reis
- Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal
| | - P Ashton-Prolla
- Hospital de Clinicas de Porto Alegre, Brazil; Hospital de Câncer de Barretos, Brazil; Faculdade de Ciências Médicas UNL, Portugal; Braga Hospital, Portugal
| |
Collapse
|
2
|
Correia RL, Oba-Shinjo SM, Uno M, Huang N, Marie SKN. Mitochondrial DNA depletion and its correlation with TFAM, TFB1M, TFB2M and POLG in human diffusely infiltrating astrocytomas. Mitochondrion 2010; 11:48-53. [PMID: 20643228 DOI: 10.1016/j.mito.2010.07.001] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2010] [Revised: 06/09/2010] [Accepted: 07/08/2010] [Indexed: 01/06/2023]
Abstract
Mitochondrial DNA (mtDNA) alterations and their clinical and pathological implications have been analyzed in several human malignancies. A marked decrease in mtDNA copy number along with the increase in malignancy was observed in diffusely infiltrating astrocytomas (24 WHO grade II, 18 grade III, and 78 grade IV or GBM) compared to non-neoplastic brain tissues, being mostly depleted in GBM. Although high relative gene expression levels of mtDNA replication regulators (mitochondrial polymerase catalytic subunit (POLG), transcription factors A (TFAM), B1 (TFB1M) and B2 (TFB2M)) were detected, it cannot successfully revert the mtDNA depletion observed in our samples. On the other hand, a strong correlation among the expression levels of mitochondrial transcription factors corroborates with the TFAM role in the direct control of TFB1M and TFB2M during initiation of mtDNA replication. POLG expression was related to decreased mtDNA copy number, and its overexpression associated with TFAM expression levels also have an impact on long-term survival among GBM patients, interpreted as a potential predictive factor for better prognosis.
Collapse
Affiliation(s)
- R L Correia
- Laboratory of Cellular and Molecular Biology, Department of Neurology, School of Medicine, University of São Paulo, Av Dr Arnaldo 455, 4th Floor, Room 4110, São Paulo, SP, 01246-903, Brazil
| | | | | | | | | |
Collapse
|